Zoetis Inc.

Zoetis Inc. announced the appointment of James Saccaro as Executive Vice President, Chief Financial Officer, and Chief Operating Officer, effective August 17, 2026. Mr. Saccaro will lead global finance functions and oversee Global Manufacturing and Supply. Concurrently, Wetteny Joseph will transition from his CFO role to a Special Advisor to the CEO until early 2027 to ensure a smooth transition. Mr. Saccaro's compensation package includes a $1,000,000 base salary, a $5,000,000 annual target long-term incentive, and one-time make-whole awards totaling $7,500,000.

Zoetis reported mixed financial results for the second quarter of 2026, with diluted earnings per share increasing to $1.65, while revenue slightly decreased to $2.468 billion and net income fell to $691 million. The company incurred significantly higher restructuring charges of $77 million, primarily due to employee termination costs. Zoetis also announced an agreement to acquire Neogen’s animal genomics business, expected to close in the second half of 2026.

Zoetis Inc. reported flat revenue of $2.5 billion for the second quarter of 2026, with reported net income decreasing 5% to $691 million. Adjusted diluted EPS increased 5% to $1.87. The company revised its full-year 2026 revenue guidance downwards to $9.12 billion - $9.32 billion, citing a pressured Companion Animal market and heightened competition. Full-year adjusted diluted EPS guidance was also lowered to $6.15 - $6.25.

Zoetis Inc. held its 2026 Annual Meeting of Shareholders on May 20, 2026, where shareholders voted on five proposals. Prior to the meeting, Ms. Louise M. Parent retired from the Board of Directors. Shareholders elected twelve directors, approved the executive compensation program on an advisory basis, and decided to hold future advisory votes on executive compensation annually. Additionally, KPMG LLP was ratified as the independent auditor, while a shareholder proposal to permit action by written consent was not approved.

Zoetis Inc. announced that its Board of Directors has declared a dividend of $0.53 per share for the third quarter of 2026. This dividend is scheduled to be paid on September 1, 2026, to all shareholders of record as of the close of business on July 20, 2026.

Zoetis Inc. announced a definitive agreement to acquire Neogen Corporation's animal genomics business, expected to close in the second half of 2026. For the first quarter of 2026, the company reported revenue of $2.26 billion, a 2.9% increase from the recast prior year. Net income attributable to Zoetis Inc. was $601 million, with diluted earnings per share of $1.42, up from $1.34 in the recast prior year, primarily due to fewer outstanding shares. The company also incurred $22 million in restructuring charges.

Zoetis Inc. reported first-quarter 2026 revenue of $2.3 billion, a 3% increase year-over-year, with net income at $601 million and diluted EPS at $1.42. Adjusted net income rose 2% to $646 million, with adjusted diluted EPS up 9% to $1.53. The company faced a challenging operating environment with increased pet owner price sensitivity and intensified competition, leading to an 8% decline in U.S. segment revenue, while international revenue grew 17%. Zoetis revised its full-year 2026 revenue guidance to $9.680 - $9.960 billion and adjusted diluted EPS guidance to $6.85 - $7.00, while also announcing the acquisition of Neogen's animal genomics business.